Korea United Pharm will expand development of obesity treatments with UNS Bio, a research and development–focused affiliate jointly established with Seoul National University Holdings.
The company said on the 26th that UNS Bio is working with researchers at the College of Pharmacy at Seoul National University to develop a small-molecule GLP-1 class novel drug. The candidate is an oral formulation and is currently in the molecule design stage, with plans to select a final candidate within the year.
In addition, the company will concurrently develop an improved long-acting GLP-1 injectable aimed at once-monthly dosing. The product is in the formulation research stage.
If development is completed, Korea United Pharm will handle commercialization, manufacturing, and sales. To that end, the company plans to renew the general solid oral dosage line at the Sejong Plant 2 and use it as production facilities for obesity treatments.